China
Africa
Explore chapters and articles related to this topic
Thermal Physiology and Thermoregulation
Published in James Stewart Campbell, M. Nathaniel Mead, Human Medical Thermography, 2023
James Stewart Campbell, M. Nathaniel Mead
“Estrogen dominance,” means having elevated estrogen levels with insufficient progesterone to balance the estrogenic effects. Although it is claimed by certain thermography centers that estrogen/progesterone dominance can be detected by certain breast heat patterns, studies addressing this subject are lacking in the scientific literature. Until such studies are performed, such claims must be evaluated with skepticism.
Managing Pain in the Presence of Autoimmune Disease
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
The gut is a vital organ for detoxification.26 Most toxins have to leave the body through defecation. This includes not only the environmental toxins such as lead and mercury but also internally generated toxins such as old, toxic estrogen metabolites.26 Every cell in our body makes toxic byproducts of metabolism that must be cleared from the body. It is vitally important to be able to clear toxins from the body efficiently and the gut is the primary organ of detoxification. An inability to clear old, toxic estrogens from the body can be one of the causes of estrogen dominance (i.e., too much estrogen compared with progesterone). Estrogen dominance is a big driver of menstrual pain, heavy flows, premenstrual syndrome, PMDD, fibroids, endometriosis, ovarian cysts, and fibrocystic breast disease.97 Insomnia and anxiety may be impacted by estrogen dominance as well. Many of these can create debilitating pain, and estrogen dominance is such a big driver of AD.18,20,22,98–101 This is one reason why more women acquire ADs than men.97
Quantitative versus qualitative estrogen and luteinizing hormone testing for personal fertility monitoring
Published in Expert Review of Molecular Diagnostics, 2021
Thomas P. Bouchard, Richard J. Fehring, Qiyan Mu
The Quantum Natural Family Planning pilot study demonstrated that the quantitative Mira monitor provided an accurate estimate of the fertile window as compared to the established reliability of the qualitative CBFM. The preliminary fertile window data we have collected with the Mira Monitor (Figure 5 and Table 2) lay the foundation for a precise, personalized, quantitative assessment the menstrual cycle for women wishing to avoid or achieve pregnancy. This quantitative approach may help in understanding normal variants and pathologies of the menstrual cycle, for example, estrogen dominance in polycystic ovarian-syndrome (PCOS) or estrogen quiescence during the postpartum or perimenopause periods, which could be delineated on a day-to-day basis, rather than relying on day-specific serum lab values that are only a snapshot in time. The use of quantitative monitoring emphasizes the importance of identifying individual patterns of hormone changes, rather than simply relying on standardized curves or approximate averages of hormones, which has been pointed out in other datasets [43]. The value of this quantitative approach requires validation in further studies with the Mira monitor in women with PCOS, during breastfeeding amenorrhea, and the perimenopause.
Methyl palmitate reversed estradiol benzoate-induced endometrial hyperplasia in female rats
Published in Toxicology Mechanisms and Methods, 2021
Adeola O. Olowofolahan, Olubukola T. Oyebode, Olufunso O. Olorunsogo
The EB-induced increase in uterine interleukin 1b level and immunoexpresion may be as a result of estrogen dominance (Li et al. 2015) due to EB administration. However, this increase was significantly ameliorated by MP co-administration, suggesting its anti-inflammatory potential and consequently, suppressing the initiation and progression of endometrial hyperplasia. The activities of uterine SOD and GSH (the antioxidant defense system enzymes) were found to be significantly reduced in the EB-treated group. This could be as a result of accumulation of reactive free radicals due to long term EB treatment. This is in agreement with Pejić et al. (2009) and Todorovic et al. (2019) who reported increase in the level of lipid hydroperoxides in tissues of patients with EH when compared to the healthy subjects. The co-administration of MP increased the activities of SOD and GSH significantly. This shows the antioxidant potential of MP against EB-induced oxidative stress in endometrial hyperplasia. This is also in accordance with the findings of Marwa and Refaie Maram (2017) who demonstrated the antioxidant property of diacerein against EB-induced increase in SOD, MDA and NOX in cervical hyperkeratosis.
Current and emerging treatment options for endometriosis
Published in Expert Opinion on Pharmacotherapy, 2018
Simone Ferrero, Giulio Evangelisti, Fabio Barra
Among the traditional first-line therapies, estroprogestins (administered orally, as transdermal patch or as vaginal ring) and progestins (administered orally, as depot injections, as implants, or by the LNG-IUS) allow for the treatment of the majority of patients with a satisfactory improvement in pain symptoms, minimal AEs, long-term safety as well as low cost [186]. While COCs have been employed for decades as the first-line treatment option for treating patients with symptomatic endometriosis, the use of progestins as a monotherapy is progressively increasing [28]. Currently, it is controversial whether estroprogestins should be preferred to progestins [187,188]. In fact, it has been hypothesized that estroprogestins, which cause supraphysiologic levels of estrogen, may theoretically be responsible for estrogen dominance in the presence of progesterone resistance, leading to endometriosis progression under its use [188].